Arcutis Biotherapeutics Inc [ARQT] stock is trading at $14.25, up 2.89%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ARQT shares have gain 12.38% over the last week, with a monthly amount drifted -4.81%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock has seen the most recent analyst activity on December 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $19. Previously, Jefferies started tracking the stock with Buy rating on August 28, 2024, and set its price target to $15. On January 03, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $8 on the stock. Mizuho downgraded its rating to a Neutral and decreased its price target to $4 on October 26, 2023. Goldman downgraded its rating to a Neutral and reduced its price target to $6 on October 13, 2023. Needham started tracking with a Buy rating for this stock on September 07, 2022, and assigned it a price target of $46. In a note dated March 17, 2022, Goldman initiated an Buy rating and provided a target price of $45 on this stock.
Arcutis Biotherapeutics Inc [ARQT] stock has fluctuated between $4.44 and $16.20 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Arcutis Biotherapeutics Inc [NASDAQ: ARQT] shares were valued at $14.25 at the most recent close of the market. An investor can expect a potential return of 33.33% based on the average ARQT price forecast.
Analyzing the ARQT fundamentals
Arcutis Biotherapeutics Inc [NASDAQ:ARQT] reported sales of 138.71M for the trailing twelve months, which represents a growth of 17.44%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.31%, Pretax Profit Margin comes in at -1.41%, and Net Profit Margin reading is -1.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -1.19 and Total Capital is -0.69. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.39 points at the first support level, and at 12.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.10, and for the 2nd resistance point, it is at 15.95.
Ratios To Look Out For
For context, Arcutis Biotherapeutics Inc’s Current Ratio is 2.46. As well, the Quick Ratio is 2.38, while the Cash Ratio is 0.78. Considering the valuation of this stock, the price to sales ratio is 12.02, the price to book ratio is 10.64.
Transactions by insiders
Recent insider trading involved Welgus Howard G., Director, that happened on Jan 02 ’25 when 10000.0 shares were sold. Director, Welgus Howard G. completed a deal on Jan 02 ’25 to buy 10000.0 shares. Meanwhile, Burnett Patrick sold 1691.0 shares on Dec 31 ’24.
